Prostate Cancer

A new study from researchers at the University of Michigan Rogel Cancer Center finds that the gene FOXA1 overrides normal biology in three different ways to drive prostate cancer. They refer to the three classes as FAST, FURIOUS, and LOUD to reflect their unique features. The findings are published in Nature.

The University of Michigan Rogel Cancer Center and the Barbara Ann Karmanos Cancer Institute at Wayne State University have received a prestigious $9.2 million grant from the National Cancer Institute for prostate cancer research.

A secondary analysis of a recent clinical trial that changed the standard of care for men with recurring prostate cancer finds long-term hormone therapy does more harm than good for many men.

The stable structure of circRNA makes it an ideal candidate for biomarkers because it can be detected in blood or urine, making it potentially useful for cancer diagnosis or prognosis.